CDER Director George Tidmarsh said on two separate events last week that he thought advisory committee meetings for specific ...

U.S. Food and Drug Administration leaders under President Donald Trump are moving to abandon a decades-old policy of asking ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

He relayed the message Tuesday at a meeting of health care product makers and Wednesday to an FDA advocacy group. In addition ...

The FDA is moving to scale back its long-standing use of expert panels to review drug applications, KFF Health News reported Sept. 12. George Tidmarsh, MD, PhD, director of the FDA’s Center for Drug ...

The Food and Drug Administration is cracking down on ingredients from potentially from unverified foreign sources and that ...

The FDA reinstated normal regulations on compounded GLP-1s after a temporary relaxation during a shortage, emphasizing safety ...

The Food and Drug Administration has created a new “green list” import alert to stop potentially unsafe GLP-1 drug ingredients, including semaglutide and tirzepatide, from entering the U.S. from ...